Dried blood spots: The future

Microsampling in Pharmaceutical Bioanalysis

Volumn , Issue , 2013, Pages 49-67

  Henion, Jack ^a   Oliveira, Regina V ^b   Li, Fumin ^c   Foley, Timothy P ^d   Pomponio, Robert J ^e  

^a Advion Inc ^*  (United States)

^b IQVIA   (United States)

^c Covance Laboratories ^*  (United States)

^d Clinical Laboratory Sciences Department at Sanofi   (United States)

^e NONE

Author keywords

Botulinum toxin; Eccrine sweat glands; Focal idiopatic hyperhidrosis

Indexed keywords

EID: 84957023180     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/fmeb2013.13.1     Document Type: Chapter

References (18)

1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32, 338-343 (1963).
2. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin. Chem. 49(11), 1797-1817 (2003).
3. Spacil Z, Tatipaka H, Barcenas M, Scott CR, Turecek F, Gelb MH. High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin. Chem. 59(3), 502-511 (2013).
4. Chambers AG, Percy AJ, Yang J, Camenzind AG, Borchers CH. Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry. Mol. Cell. Proteomics 12(3), 781-791 (2013).
5. Prince PJ, Matsuda KC, Retter M, Scott G. Assessment of DBS technology for the detection of therapeutic antibodies. Bioanalysis 2(8), 1449-1460 (2010).
6. Beaudette P, Bateman KP. Discovery stage pharmacokinetics using dried blood spots. J. Chromatogr. B Anal. Tech. Biomed. Life Sci. 809(1), 153-158 (2004).
7. Xu Y, Woolf EJ, Agrawal NG, Kothare P, Pucci V, Bateman KP. Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how. Bioanalysis 5(3), 341-350 (2013).
8. Booth B. Stuff we get asked about: DBS and biomarker FAQs. Presented at: Applied Pharmaceutical Analysis 2012. Baltimore, MD, USA, 16-19 September (2012).
9. Timmerman P, White S, Globig S, LÜdtke S, Brunet L, Smeraglia J. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis 3(14), 1567-1575 (2011).
10. Walter JH. Neonatal screening for PKU and other metabolic disorders. Semin. Neonatol. 3(1), 17-25 (1998).
11. Duffey TA, Bellamy G, Elliott S et al. A tandem mass spectrometry triplex assay for the detection of fabry, pompe, and mucopolysaccharidosis-I (Hurler). Clin. Chem. 56(12), 1854-1861 (2010).
12. Ryall RG, Gjerde EM, Gerace RL, Ranieri E. Modifying an enzyme immunoassay of immunoreactive trypsinogen to use time-resolved fl orescence. Clin. Chem. 39(2), 224-228 (1993).
13. De Mulder M, Holguín Á. [Dried blood spots for monitoring HIV infection in public health programs in developing countries]. Enferm. Infecc. Microbiol. Clin. 31(2), 100-107 (2013).
14. Demirev PA. Dried blood spots: analysis and applications. Anal. Chem. 85(2), 779-789 (2013).
15. Woolley CF, Hayes MA. Recent developments in emerging microimmunoassays. Bioanalysis 5(2), 245-264 (2013).
16. Jolicoeur P, Tacey RL. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. Bioanalysis 4(24), 2959-2970 (2012).
17. Krastins B, Prakash A, Sarracino DA et al. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 46(6), 399-410 (2013).
18. Zhang Y. Policies for handling residual newborn blood samples for human health research. Clin. Chem. 59(4), 716 (2013).